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Abstract
Classic homocystinuria is due to deficiency of cystathionine beta-synthase (CBS), a
pyridoxine-dependent enzyme that, depending on the molecular variants, may be co-
factor responsive. Elevated methionine is often used as the primary analyte to detect
CBS deficiency (CBSD) on newborn screening (NBS), but is limited by increased
detection of other biochemical disorders with less clear clinical significance such as
methionine aminotransferase (MAT) I/III heterozygotes. Our state has implemented a
two-tier NBS algorithm for CBSD that successfully reduced the number of MATI/III
heterozygotes, yet effectively detected a mild, co-factor responsive form of CBSD.
After initial diagnosis, newborns with CBSD often undergo a pyridoxine challenge
with high-dose pyridoxine to determine responsiveness. Here we describe our NBS-
identified patient with a mild form of pyridoxine responsive CBSD who developed
respiratory failure and rhabdomyolysis consistent with pyridoxine toxicity during a
pyridoxine challenge. This case highlights the need for weight-based dosing and
duration recommendations for pyridoxine challenge in neonates.
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1 | INTRODUCTION
The state of Michigan began screening for homocystinuria and related
disorders in 2004 using an elevated methionine as the primary ana-
lyte. The methionine:phenylalanine ratio (Met/Phe) is also included in
the first-tier screening algorithm as it allows for comparison of multi-
ple amino acids that may be elevated nonspecifically due to transient
dietary differences, use of total parenteral nutrition, or general liver
health (Morris et al., 2017; Okun et al., 2017). In 2015, Michigan
implemented a second tier assay to improve specificity of methionine
and Met/Phe as primary analytes [allowing newborn screening (NBS)
to keep cystathionine beta-synthase deficiency (CBSD) false positives
to a minimum] given that elevated methionine is seen in a number of
conditions including methionine aminotransferase (MAT) I/III hetero-
zygotes without clear clinical significance (Huemer et al., 2015; Keller
et al., 2019; Sen, Felice, Bannick, Colombo, & Conway, 2019). Cur-
rently for samples from term newborns not admitted to the neonatal
intensive care unit with a methionine ≥45 μmol/L and a Met/Phe
≥1.0, the initial NBS dried blood spot is sent to a reference lab (Mayo
Medical Laboratories, Rochester, MN) to perform second-tier analysis
of total homocysteine. If the total homocysteine level is greater than
15 μmol/L, the sample is considered a presumptive positive and pro-
mpts a referral to a metabolic follow-up clinic. To allow for timely
management of more severe cases of CBSD, NBS samples withAmes EG and Scott AJ contributed equally to this study.
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methionine ≥80 μmol/L and Met/Phe ≥1.0 are considered presumptive
positives and directly referred to a metabolic clinic for diagnostic testing.
Between 2004 and 2014, prior to the initiation of second-tier anal-
ysis of total homocysteine, there were 64 presumptive positive new-
born screens prompting referral to a metabolic center. Confirmatory
testing identified 3 confirmed cases of CBSD (none were pyridoxine
responsive) and 12 cases of persistent isolated hypermethioninemia, all
due to severe or partial MATI/III deficiency. There was one case of a
mother with autosomal recessive MAT1A deficiency whose methionine
ranged from 800 to 1,400 μmol/L whose child's methionine levels nor-
malized with confirmatory testing (Table 1). The remaining cases were
all false positives. The positive predictive value of detecting CBSD with
elevated methionine over this time was 4.7% (3 true positives/64 total
positive screens). Since initiation of two-tier screening, there were
7 presumptive positive referrals based on methionine elevation and ele-
vated Met/Phe. None of these were confirmed to have CBSD. In addi-
tion, 57 samples were sent for second-tier testing. Of those
57 samples, only 3 were found to have elevated homocysteine levels.
Upon confirmatory testing, two cases were found to be unaffected and
the third case, as described below, was found to have pyridoxine-
responsive CBSD (Table 1). The positive predictive value of detecting
CBSD with second-tier screening with homocysteine was 10% (1 true
positive/10 total positive screens).
Our patient was identified by NBS to have an elevated methionine
(73 μmol/L, normal <45) and elevated Met/Phe ratio (1.6, normal <1.0).
Second-tier testing was notable for an elevated homocysteine
(21.9 nmol/ml, normal <15). Confirmatory plasma amino acids were
obtained on day of life 8 that were notable for a mildly elevated methionine
(54 μmol/L, normal 23–43) and elevated homocysteine (40 μmol/L, normal
5–15). Vitamin B12 (592 pg/ml) and folate (>22.3 ng/ml) levels were both
normal. Molecular testing for hypermethioninemia including the CBS,
GNMT, MAT1A, and ACHY genes was sent. Additional metabolites of the
methionine pathway (S-adenosylmethionine and S-adenosylhomocysteine)
were unable to be sent due to insufficient blood volume.
Following these confirmatory labs, the patient was diagnosed
with presumptive CBSD and started on pyridoxine at a dose of
100 mg daily (31 mg/kg/day) as a trial to determine pyridoxine
responsiveness without introduction of medical formula. Homocyste-
ine measured 7 days after pyridoxine initiation was again stably ele-
vated (44 μmol/L). With no significant reduction in homocysteine
level, pyridoxine dosing was increased to 200 mg daily (54 mg/kg/
day) with a plan to recheck levels in 1 week. Roughly 1 week after
dose increase (2 weeks of pyridoxine therapy), the patient suddenly
developed dyspnea and cyanosis, followed by apnea, causing the care-
giver to perform CPR. The patient was then transported via EMS to
the Emergency Department (ED) for further evaluation.
TABLE 1 Hcy = homocysteine, Pres + = presumptive positive, T+ CBSD = true positive CBS deficiency, Hyper Met = persistent isolated
hypermethioninemia, Mat MAT1A = maternal autosomal recessive MAT1A deficiency
Year Hcy second tier + Second tier Pres + T+ CBSD Hyper Met Mat MAT1A
Changes to methionine cutoff
and/or platform
2004 (October) 6 0 0 0 Met = 87 μmol/L, M/P ≥ 1.3
2005 10 0 0 0
2006 7 0 0 0
2007 1 0 0 0 Met = 74 μmol/L, M/P ≥ 1.3
2008 1 0 1 0
2009 2 1 1 0
2010 6 0 3 0
2011 7 0 3 0 Met = 56 (switch from NeoGram
to NeoBase)
2012 11 2 2 1
2013 5 0 1 0
2014 8 0 1 0
2015 (January) 7 2 2 0 0 0
2016 6 0 2 0 0 0
2017 18 0 2 0 1 0
2018 11 0 1 0 0 0
2019 15 1 0 1 0 0 Met = 45 (switch from NeoBase
to NeoBase2)
Hcy second tier + second tier Pres + T+ CBSD Hyper Met Mat MAT1A
Pre-second tier 64 3 12 1
Post-second tier 57 3 7 1 1 0
Abbreviations: Hcy, homocysteine; Hyper Met, persistent isolated hypermethioninemia; Mat MAT1A, maternal autosomal recessive MAT1A deficiency;
Pres +, presumptive positive; T+ CBSD, true positive CBS deficiency.
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On arrival to the ED, the patient initially appeared comfortable
with even and unlabored respirations, but was noted to have intermit-
tent peripheral arterial desaturations by pulse oximetry to SpO2
88–89% with exam. The patient continued to have intermittent
apneic episodes lasting 30–40 s that progressed to more significant
desaturations (SpO2 70–79%) with subsequent bradycardia of 60–69
beats/min. Given the increased frequency of apneic episodes and bra-
dycardia, she was intubated. The patient was then transferred to the
pediatric intensive care unit for further management and close moni-
toring of her respiratory failure. Labs on admission were notable for
elevated transaminases (AST 422, ALT 137 IU/L), elevated creatine
kinase (CK) (5,973 IU/L, normal 26–180), homocysteine of 37 μmol/L,
and methionine of 131 μmol/L. A broad spectrum of testing for other
causes of apnea in a newborn was negative, including a full sepsis
evaluation with CSF studies, viral respiratory PCR panel, brain MRI,
and long-term video EEG. Pediatric Genetics was consulted for further
management of homocystinuria.
Based on her clinical presentation of apnea leading to respiratory
failure, elevated transaminases, and elevated CK, pyridoxine toxicity
was strongly suspected and genetics recommended cessation of pyri-
doxine until improvement of her clinical picture and molecular confir-
mation of her diagnosis. Within 72 hr of pyridoxine cessation, the
patient's respiratory drive had improved and she was extubated to
noninvasive positive pressure ventilation for several days before being
weaned to supplemental oxygen via nasal cannula. While she was crit-
ically ill, enteral feeding was held and nutrition was provided via
dextrose-containing fluids and intravenous lipids.
During her admission, the results of molecular testing returned
and revealed two pathogenic variants in the CBS gene: c.833T>C, p.
Ile278Thr and c.476_477insCAGGCCC, p.Val160Argfs*4, the latter of
which has not been previously described. The former is a pathogenic
variant that is associated with pyridoxine-responsive CBSD. Prior to
discharge and 7 days after admission, her elevations in CK, AST, and
ALT continued to downtrend and pyridoxine was reinitiated at
10 mg/kg dose prior to discharge. Although she clearly did not
respond clinically in a classic pyridoxine-responsive manner,
genotype–phenotype correlation of CBS compound heterozygotes is
difficult to predict (Morris et al., 2017), and a safe dose of pyridoxine
was continued to provide potential benefit in the event that she was
partially responsive to pyridoxine.
Labs performed 1 week after hospital discharge on a breast
milk-based diet were notable for a normal CK, normal AST/ALT, a homo-
cysteine of 56 μmol/L, and methionine of 268 μmol/L. Due to maternal
concerns about pyridoxine toxicity, patient's pyridoxine dose was less
than what we recommended (ultimately around 7–8 mg/kg/day instead
of recommended 10–20 mg/kg/day). Repeat labs 1 week later revealed
a homocysteine of 59 μmol/L and methionine of 589 μmol/L, but these
were noted to be post-prandial samples. Preprandial labs repeated
1 week later were again notable for persistent elevations in methionine
(641 μmol/L) and homocysteine (66 μmol/L). A partial methionine-
restricted diet was initiated (total methionine intake of 25–30 mg/kg/day)
and subsequent labs were notable for a methionine of 77 μmol/L and a
homocysteine of 39 μmol/L. At 6 months of age, she has continued
on pyridoxine 10 mg/kg/day and a partial methionine-restricted diet.
She has attained age-appropriate milestones and has normal growth
parameters. Her methionine levels are below 100 μmol/L and her
homocysteine levels are below 50 μmol/L.
2 | DISCUSSION
Classic homocystinuria or CBSD is the most common inborn error of
sulfur metabolism due to pathogenic variants in the CBS gene
(Kruger, 2017). There is a wide range of presentations based on the
severity of the disease and include developmental delay, ectopia len-
tis, Marfanoid habitus, osteoporosis, intellectual disability, thrombo-
embolic events, and even some reports of asymptomatic adults.
(Gibson, Carson, & Neill, 1964; Poloni et al., 2018). From a biochemi-
cal perspective, there is also a wide range of phenotypes including
mild homocysteine elevations that are highly responsive to pyridoxine
compared with pyridoxine-unresponsive forms that require extensive
methionine restriction and medical management with betaine. One of
the most common pathogenic variants in the CBS gene is c.833T>C (p.
Ile278Thr) which accounts for approximately 25% of all pathogenic
variants identified and is pan-ethnic (Moat et al., 2004). The p.
Ile278Thr variant is associated with at least some degree of pyridox-
ine responsiveness (Morris et al., 2017) and results in a less severe dis-
ease phenotype (Kluijtmans et al., 1999; Shih et al., 1995).
Epidemiologic studies suggest that the expected incidence of individ-
uals with CBSD—especially when taking into account the frequency
of the p.Ile278Thr allele—should be much more than the frequency of
those actually identified by standard NBS methods (Gaustadnes,
Ingerslev, & Rutiger, 1999). Similarly, one study suggested that NBS
will only identify 25% of CBSD cases when hypermethioninemia is
used as the primary analyte (Sokolová et al., 2001). The recently publi-
shed guidelines for CBSD emphasize this point. The sensitivity of
CBSD detection by NBS with hypermethioninemia alone is probably
very low unless paired with a two-tier system (Huemer et al., 2015;
Keller et al., 2019; Morris et al., 2017) as our state has implemented.
To our best estimate, the incidence of CBSD in Michigan for October
2004 through January 2015 is 1:400,000 (calculated on total number
of NBS performed each year with the exception of 2005 where data
is not available, a stable birth rate compared with 2006 was assumed).
The incidence of CBSD in Michigan between February 2015 to
December 2019 is estimated to be 1:500,000 (calculated on total
number of NBS performed with the exception of 2019 where data
has not been reported yet and the birth rate was assumed to be stable
compared with 2018). In comparison, our estimation of CBSD inci-
dence based on clinically ascertainment prior to NBS is roughly 1 in
1,000,000 (assuming Michigan has roughly 100,000 births per year
and we have on average one CBSD patient per decade who predate
NBS. Our state's data supports that the two-tier screening system
improves the positive predictive value of NBS while overall detecting
a similar number of patients. The primary benefit of such a two-tier
system, when methionine is the primary analyte for detection, is that
this approach allows for lower methionine cutoffs to detect mild
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forms of CBSD while resulting in a relatively low number of referrals
by improving specificity with a second tier screening of total homo-
cysteine level as has been reported elsewhere (Alodaib et al., 2012;
Keller et al., 2019; Mudd, 2011; Turgeon et al., 2010). In our state, we
have shown that many of the elevations of methionine found through
NBS were ultimately due to confirmed or presumed mutations in
MAT1A, the gene responsible for MAT I/III deficiency (Sen
et al., 2019). However, utilizing a two-tier approach allowed NBS to
successfully discriminate a true and mild case of CBSD.
Adverse effects to pyridoxine have been previously reported in
other neonates with apnea after receiving high doses of pyridoxine
(Mudd, Levy, & Kraus, 2001). Our patient's presentation was similar to
a Japanese infant with CBSD who received 100 mg/kg for 8 days
before she developed apneic respiratory failure, rhabdomyolysis, and
elevated transaminases; the infant recovered fully over a few weeks
after pyridoxine cessation (Shoji, Takahashi, Sato, Shoji, &
Takada, 1998). There are several differences between this case and
our patient. Our patient was only prescribed 200 mg daily (54 mg/kg/
day) for 7 days following a 7-day period of receiving 100 mg daily
(31 mg/kg/day). The neonate described in Shoji et al. also had mark-
edly elevated methionine levels (1,340–1,630 μmol/L) whereas our
patient had less significant hypermethionemia (methionine
<1,000 μmol/L). Our case suggests a lower dose can cause pyridoxine
toxicity in early infancy. In the guidelines for CBSD management, a
pyridoxine challenge of 10 mg/kg/day is recommended for at least
7 days. However, there is a special exception for neonates detected
by NBS who are presumed to be more severe and less likely to
respond to pyridoxine and should receive a relatively high dose of
pyridoxine (100 mg/day) for 2 weeks (Morris et al., 2017). These
guidelines also report a range of doses for pyridoxine challenge of
100–500 mg/day for 1–2 weeks, which for a 3–4 kg neonate is a min-
imum dose of 25–33 mg/kg/day to a maximum dose of 125–167 mg/
kg/day. The management guidelines proposed in GeneReviews rec-
ommends a pyridoxine challenge of a shorter duration to find the low-
est possible dose to produce the maximum biochemical benefit
(defined as 30% or more reduction in homocysteine). For neonates
detected by NBS this would entail 100 mg/day for 2 days (25–33 mg/
kg/day assuming 3–4 kg neonate), checking methionine and homocys-
teine levels, and two additional dose escalations over the next 4 days
to 200 mg/day (50–66 mg/kg/day) and 300 mg/day (75–100 mg/kg/
day) to determine pyridoxine responsiveness (Sacharow, Picker, &
Levy, 2004). Commonly used biochemical textbooks vary in their
recommendations for pyridoxine challenge including 100 mg daily for
2 weeks (Saudubray, Baumgartner, & Walter, 2016) to a dose escala-
tion from 100 mg daily (25–33 mg/kg/day) to 500 mg daily
(125–167 mg/kg/day) over multiple weeks (Blau, Duran, Gibson, &
Dionisi-Vici, 2014).
Our case highlights the importance and risks associated with pyri-
doxine challenge in neonates with CBSD. The current clinical practice
guidelines and literature for pyridoxine challenges does not clearly dis-
criminate recommended doses based on age, weight, and suspicion of
clinical pyridoxine responsiveness (as indicated by homocysteine
level). The recommendations for dose escalation in a pyridoxine
challenge may not be appropriate for all infants. It is also possible that
additional factors, as yet undetermined, may predispose some neo-
nates to toxic effects of pyridoxine at doses which are well tolerated
by other neonates. Until the risks of pyridoxine toxicity are better
understood, current recommendations could be strengthened by clear
weight-based dosing and duration for pyridoxine therapy, especially
for neonates detected by NBS when assessing for co-factor respon-
siveness. As molecular testing confirmation becomes more widely
available, the knowledge of specific pathogenic variants may also be a
crucial determinant in the pyridoxine responsiveness and the pyridox-
ine dose escalation chosen by providers. We propose that for neo-
nates with CBSD detected by NBS that a pyridoxine challenge would
be completed over a relatively short period of time and with a careful
review with parents of the adverse side effects associated with pyri-
doxine toxicity including risk of apnea. Given that our patient had clin-
ically significant apnea at 50 mg/kg/day, we would recommend
starting at 10 mg/kg/day for 4 days, increasing to 20 mg/kg/day for
4 days if no appreciable change in homocysteine level, and using
40 mg/kg/day as a maximum dose for another 4 days. We recom-
mend extreme caution in neonates for doses approaching or in excess
of 200 mg daily and to use weight-based doses when possible. Pyri-
doxine is also used for patients with pyridoxine dependent epilepsy
with a recommended maximum dose of 40 mg/kg/day for short
periods of time during illnesses (van Karnebeek et al., 2015). While
this disorder has a completely different mechanism, it is another help-
ful measure of what is generally considered safe by weight-based
standards. We acknowledge that future case reports or therapeutic
studies may alter our recommendations. We encourage providers to
proceed with caution when selecting doses for performing neonatal
pyridoxine challenges for NBS-detected patients with CBSD and fol-
low neonates closely for pyridoxine toxicity or side effects.
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